Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC3141 for COVID-19-related ARDS in ICU patients
ACTRN12620000588998Phase 2Withdrawn
- Sponsor
- Grand Medical Group AG
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of STC3141 in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Grand Medical Group AG. Primary endpoints: Change in PaO2/FiO2, Incidence, nature and severity of adverse events and serious adverse events and 1 more. Planned start May 2020; status: withdrawn.
02
Drugs
STC3141
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ACTRN12620000588998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000588998.